Gillard, Michel

Synaptic Vesicle Glycoprotein 2A Ligands in the Treatment of Epilepsy and Beyond

Löscher, W., Gillard, M., Sands, Z. A., Kaminski, R. M., & Klitgaard, H. (2016) · CNS Drugs

Epilepsy research and treatmentNeuroscience and Neuropharmacology Research

Cited by 184

Brivaracetam: Rationale for discovery and preclinical profile of a selective SV 2A ligand for epilepsy treatment

Klitgaard, H., Matagne, A., Nicolas, J., Gillard, M., Lamberty, Y., De Ryck, M., Kaminski, R. M., Leclercq, K., Niespodziany, I., Wolff, C., et al. (2016) · Epilepsia

Epilepsy research and treatmentPharmacological Effects and Toxicity Studies

Cited by 168

Binding characteristics of levetiracetam to synaptic vesicle protein 2A (SV2A) in human brain and in CHO cells expressing the human recombinant protein

Gillard, M., Chatelain, P., & Fuks, B. (2006) · European Journal of Pharmacology

Neuroscience and Neuropharmacology ResearchEpilepsy research and treatment

Cited by 148

The tau positron-emission tomography tracer AV-1451 binds with similar affinities to tau fibrils and monoamine oxidases

Vermeiren, C., Motte, P., Viot, D., Mairet‐Coello, G., Courade, J., Citron, M., Mercier, J., Hannestad, J., & Gillard, M. (2018) · Movement Disorders

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 143

Evaluation of18F-UCB-H as a Novel PET Tracer for Synaptic Vesicle Protein 2A in the Brain

Warnock, G. I., Aerts, J., Bahri, M. A., Bretin, F., Lemaire, C., Giacomelli, F., Mievis, F., Mestdagh, N., Buchanan, T., Valade, A., et al. (2014) · Journal of Nuclear Medicine

Radiopharmaceutical Chemistry and ApplicationsMedical Imaging Techniques and Applications

Cited by 85

[11C]UCB-A, a novel PET tracer for synaptic vesicle protein 2A

Estrada, S., Lubberink, M., Thibblin, A., Sprycha, M., Buchanan, T., Mestdagh, N., Kenda, B., Mercier, J., Provins, L., Gillard, M., et al. (2016) · Nuclear Medicine and Biology

Radiopharmaceutical Chemistry and ApplicationsMedical Imaging Techniques and Applications

Cited by 71

Mechanisms underlying allosteric modulation of antiseizure medication binding to synaptic vesicle protein 2A (SV2A)

Mittal, A., Martin, M. F., Provins, L., Hall, A., Ledecq, M., Wolff, C., Gillard, M., Horanyi, P. S., & Coleman, J. A. (2025) · Proceedings of the National Academy of Sciences

Neuroscience and Neuropharmacology ResearchEpilepsy research and treatment

Cited by 7